Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Recueil de poésies, par « HENRY BAULDE » (fol. 30, 32, 35, 36, 37, 39, 40, 43, 44, 46, 47, 56, 59, 60, 61, 65, 68, 69, 70, 73, 74), « ALAIN CHARRETIER » (fol. 15), « JEHAN DAUTON » (fol. 9), « JEHAN MAROT » (fol. 29, 30), « JEHAN MOLINET » (fol. 77, 85, 90, 93, 94, 95) et « JEHAN ROBERTET » (fol. 1, 75).

Commençant par : « Estant couché soubz ung myrthe plaisant, Et maintz chasteaulx en Espaigne faisant... » et finissant par : « Sans parage ou riens n'est nect, Moulu d'un groz Moulinet. Fin de la complaincte de Grece, composée par le dict Molinet » .

Resolución N° 90 del 18 de mayo de 2010 ¿Seria violatoría la reunión por derecho propio aun en contra de la voluntad de los administradores o socios?

Servicios registrales

The War, 8 March 1814 (vol. 2, no. 38, whole no. 90) - Newspaper

Volumes of interest were published between 1812 and 1815 with articles about the War of 1812.

Real-Time Automatic Object Classification and Tracking using Genetic Programming and NVIDIA R CUDA TM

Genetic Programming (GP) is a widely used methodology for solving various computational problems. GP's problem solving ability is usually hindered by its long execution times. In this thesis, GP is applied toward real-time computer vision. In particular, object classification and tracking using a parallel GP system is discussed. First, a study of suitable GP languages for object classification is presented. Two main GP approaches for visual pattern classification, namely the block-classifiers and the pixel-classifiers, were studied. Results showed that the pixel-classifiers generally performed better. Using these results, a suitable language was selected for the real-time implementation. Synthetic video data was used in the experiments. The goal of the experiments was to evolve a unique classifier for each texture pattern that existed in the video. The experiments revealed that the system was capable of correctly tracking the textures in the video. The performance of the system was on-par with real-time requirements.

HG 238.80-238.90 Thin Section

Dark brown sediment with clasts ranging from small to medium in size and sub-angular to angular. Contains lineations and grain stacking throughout the sample. Rotation and comet structures can also be seen. Rotation structures can be seen around mainly the sub-angular clasts. Patches of clay can also be seen throughout the sample.

DE #6 260.90-261.0

Coarse grained sediment with clasts ranging from small to medium in size. Clast shape range from sub-angular to sub-rounded. Lineations are present throughout the sample. Edge-to-edge grain crushing, grain stacking, and comet structures can also be seen. Some grains are crushed into one another. Areas of finer sediment can also be seen.

HG 367.80-367.90

Dark grey sediment with clasts that range from small to medium. The clasts are mainly sub-rounded. Lineations are abundant with minor amounts of rotation structures and comet structures. Grain crushing can also be seen throughout the sample.

HG 493.80-493.90

Coarse brown sediment, with clasts ranging from small to large in size. Clast shape ranges from sub-angular to rounded. Lineations and grain crushing are common throughout the sample. It also contains comet structures and a few rotation structures. Many of the larger clasts are also fractured.

HG 28.75-28.90

This sample contains clasts that range from small to large. A few fractured grains can be seen. The grain shape ranges from angular to rounded. Rotation structures can be seen throughout the sample along with some edge-to-edge grain crushing.